Newsfeeds Archive - Spark Newswire

4 minute read

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

May 28, 1:24 PM

Shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) fell sharply during Tuesday’s session after the company announced the pricing…

ABL

3 minute read

Crude Oil Rises 1%; Verastem Shares Slide

By Avi Kapoor

May 24, 2:47 PM

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on…

AKAN

4 minute read

Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Avi Kapoor

May 24, 1:57 PM

Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday’s session after the company reported worse-than-expected first-quarter revenue. NetEase reported…

AEI

2 minute read

Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?

By Vandana Singh

May 24, 1:41 PM

Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with a 60% response rate.

MRK

3 minute read

Nasdaq Gains 1%; Intuit Shares Plunge

By Avi Kapoor

May 24, 12:07 PM

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Friday. The Dow…

AKAN

2 minute read

Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday

By Avi Kapoor

May 24, 10:12 AM

U.S. stocks were higher, with the Nasdaq Composite gaining around 80 points on Friday. Shares of Deckers Outdoor…

AZUL

2 minute read

Merus Announces U.S. FDA Acceptance And Priority Review Of BLA For Zeno For The Treatment Of NRG1+ NSCLC And PDAC

By Benzinga Newsdesk

May 6, 4:28 PM

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the

MRUS

1 minute read

Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024

By Benzinga Newsdesk

April 8, 12:03 PM

Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced

MRUS

2 minute read

Analyst Ratings

Expert Ratings for Merus

By Benzinga Insights

November 28, 8:00 AM

Merus (NASDAQ:MRUS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

MRUS

5 minute read

Merus Announces Publication Of Abstracts On MCLA-129 For Presentation At ESMO Asia Congress 2023

By Benzinga Newsdesk

November 27, 12:44 AM

- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT - Poster presentation on MCLA-129 in

MRUS